The FDA has placed a partial clinical hold on a Phase I study of Foghorn Therapeutics’ investigational protein degrader FHD-609 after a patient developed a grade 4 QTc prolongation event, the company announced Monday.
https://www.pharmalive.com/wp-content/uploads/2022/02/FDA-Ad-Com-Comes-Down-Hard-on-Avenues-IV-Tramadol-BioSpace-2-16-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-04-25 10:37:332023-04-25 10:37:33FDA presses pause on another Foghorn program
